<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962156</url>
  </required_header>
  <id_info>
    <org_study_id>2008-262</org_study_id>
    <secondary_id>EudraCT no. 2009-010104-28</secondary_id>
    <nct_id>NCT00962156</nct_id>
  </id_info>
  <brief_title>Scandinavian Starch for Severe Sepsis/Septic Shock Trial</brief_title>
  <acronym>6S</acronym>
  <official_title>Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Perner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  By tradition hydroxyethyl starch (HES) is used to obtain fast circulatory stabilisation
           in critically ill.

        -  High molecular weight HES may, however, cause acute kidney failure in patients with
           severe sepsis.

        -  Now the low molecular weight HES 130/0.4 is the preferred colloid in Scandinavian
           intensive care units (ICU) and 1st choice fluid for patients with severe sepsis.

        -  HES 130/0.4 is largely unstudied in ICU patients.

        -  This investigator-initiated Scandinavian multicentre trial will be conducted to assess
           the effects of HES 130/0.4 on mortality and endstage kidney failure in patients with
           severe sepsis.

        -  The trial will provide important data to all clinicians who resuscitate septic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluid is the mainstay treatment in sepsis resuscitation, but the effects of different
      crystalloid and colloid solutions on outcome remain unknown.

      Previously, a high molecular weight hydroxyethyl starch, HES 200, was used, but this was
      found to cause acute kidney failure in patients with severe sepsis. As kidney failure is an
      independent risk factor for death in these patients, HES 200 is not used anymore. In stead a
      lower molecular weight starch, HES 130, has been developed. Presently, this is the preferred
      colloid in Scandinavian intensive care units (ICU), but the effects of HES 130 in ICU
      patients are currently unknown. The proposed Scandinavian multicentre study will be conducted
      to assess if HES 130 contributes to acute kidney failure in patients with severe sepsis. As
      HES 130 is widely used, the trial will provide important safety data to clinicians who
      resuscitate septic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality or dialysis-dependency</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity organ failure assessment score</measure>
    <time_frame>Day 5</time_frame>
    <description>Excluding Glascow coma score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days free of ventilation</measure>
    <time_frame>90 days</time_frame>
    <description>Among survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days free of dialysis</measure>
    <time_frame>90 days</time_frame>
    <description>Among survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse reactions</measure>
    <time_frame>Followed up until ICU discharge; consequently the time frame will vary among patients</time_frame>
    <description>Severe bleeding or severe allergic reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of dialysis/haemofiltration</measure>
    <time_frame>Within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of ventilation</measure>
    <time_frame>Within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney failure</measure>
    <time_frame>Followed up until ICU discharge; consequently the time frame will vary among patients</time_frame>
    <description>Severity organ failure assessment score &gt; 2 in the renal component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation analyses</measure>
    <time_frame>5 days</time_frame>
    <description>At selected hospitals whole-blood and biochemical coagulation analyses constitute additional secondary endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NGAL</measure>
    <time_frame>5 days</time_frame>
    <description>At selected trial sites will plasma and urinary NGAL be analysed at randomisation to assess the predictive value for dialyse and kidney failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">804</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>HES 130/0.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volume expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ringer acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volume expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6% Hydroxyethyl starch 130/0.4</intervention_name>
    <description>Infusion for volume expansion in the ICU</description>
    <arm_group_label>HES 130/0.4</arm_group_label>
    <other_name>6% Tetraspan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringers acetate</intervention_name>
    <description>Infusion for volume expansion in the ICU</description>
    <arm_group_label>Ringer acetate</arm_group_label>
    <other_name>Ringerfundin / Sterofundin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All adult patients who

          -  Undergo resuscitation in the ICU

          -  AND fulfillment within the previous 24 hours of the criteria for severe sepsis
             (SCCM/ACCP)

          -  AND consent is obtainable either from the patient or by proxy (physician and/or next
             of kin)

        Exclusion Criteria:

        The following patients will not be evaluated for inclusion:

          -  Age &lt; 18 years old

          -  Previously randomised in the 6S trial

          -  Allergy towards hydroxyethyl starch or malic acid

          -  Treatment with &gt; 1000 ml's of any synthetic colloid within the last 24 hours prior to
             randomisation

          -  Any form of renal replacement therapy

          -  Acute burn injury &gt; 10% body surface area

          -  Severe hyperkalaemia, p-K &gt; 6 mM

          -  Liver or kidney transplantation during current hospital admission

          -  Intracranial bleeding within current hospitalisation

          -  Enrollment into another ICU trial of drugs with potential action on circulation, renal
             function or coagulation

          -  Withdrawal of active therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Perner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICU, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolai Haase, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hosptial</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esbjerg Hospital</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hjørring Hospital</name>
      <address>
        <city>Hjørring</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Køge Hospital</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Næstved Hospital</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sønderborg Hospital</name>
      <address>
        <city>Sønderborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Intensive Care, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Intensive Care, Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Landspitali</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital, Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bødker KD, Bådstøløkken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow HH, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, Pettilä V, Ruokonen E, Klepstad P, Karlsson S, Kaukonen M, Rutanen J, Karason S, Kjældgaard AL, Holst LB, Wernerman J; Scandinavian Critical Care Trials Group. Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials. 2011 Jan 27;12:24. doi: 10.1186/1745-6215-12-24.</citation>
    <PMID>21269526</PMID>
  </reference>
  <results_reference>
    <citation>Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012 Jul 12;367(2):124-34. doi: 10.1056/NEJMoa1204242. Epub 2012 Jun 27. Erratum in: N Engl J Med. 2012 Aug 2;367(5):481.</citation>
    <PMID>22738085</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Scandinavian Critical Care Trials Group</investigator_affiliation>
    <investigator_full_name>Anders Perner</investigator_full_name>
    <investigator_title>Chairman</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Shock</keyword>
  <keyword>Fluid therapy</keyword>
  <keyword>Plasma expanders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

